Annual reportSep 2026
Sep 2026 · Weblink Letter To Shareholders - Pursuant To Regulation 36(1)(B) Of SEBI (LODR) Regulations, 2015 3 Sep - 11th AGM on September 28, 2026; FY2025-26 annual report and e-voting details shared.
Source: Bse
Gaudium IVF and Women Health Limited (GAUDIUMIVF)
Small CapPharma stocks · Small cap · NSE
Gaudium IVF and Women Health Limited operates in Fertility Clinics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 01:15 pm ISTDetails
Quote21 Oct, 01:15 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:05 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
62BullishSMA20 -7.9% / mo · MACD − · sector +4.6pp vs Nifty 500 (3M)
Stock trend: 36
Sector RS: 100
Sector 3M: -1.5% vs Nifty 500 -6.0%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
GAUDIUMIVFD candles · FIT view-25.9%TODAY · PROVISIONALLatest price ₹95.02 on 2026-10-21
Daily history is available from 2026-02-27; the requested 1Y window is partially covered. Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-3.0%
RSI
29
MACD hist
-0.86
52W pos
27%
2026-10-21O ₹97.97H ₹100.73L ₹93.85C ₹95.02Vol 1.6L shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
GAUDIUMIVFNifty PharmaNifty 500
- GAUDIUMIVF
- -34.1%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -28.5 pp
Chart stats
19 Oct 2026- From 52W high
- -40.2%
- 52W range position
- 30%
- ATR (14)
- 5.9%
- Volume vs 20D
- 0.97x
- Avg traded value
- ₹2.5 Cr
- 20D price channel
- ₹96.1 - ₹123
₹163.2
₹69.2 - ₹163.2
₹5.8
Latest completed session
20-session average
45.0% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · FAIR VALUE56
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +9.1% · PAT -42.0% YoY
Technical
Bullish62
Price trend and sector-relative-strength timing.
Valuation
Legacy model+39.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence67
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -42% YoY · margin compression · Rev +9% YoY
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹19.4 Cr | +9.1% | -36.1% |
| EBITDA | ₹2.4 Cr | -52.8% | -80.0% |
| Operating margin | 12.5% | -1646 bps | -2756 bps |
| PAT | ₹1.8 Cr | -42.0% | -78.7% |
| PAT margin | 9.2% | -811 bps | -1837 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 32.40
- P/B
- 4.93
- EV/EBITDA
- 20.95
- Market Cap
- 750.00Cr
Profitability
- ROE
- 24.70%
- ROCE
- 29.30%
- ROA
- 11.92%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 41.00%
- EPS 5Y
- 41.00%
- Revenue 3Y
- 33.00%
- EPS 3Y
- 22.00%
Balance Sheet
- Debt/Equity
- 0.16
- Interest Coverage
- 11.67×
- Altman Z
- 8.27
- Book Value
- 20.90
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- 7.00 Cr
- EPS TTM
- 3.51
Shareholding
- Promoter Hold
- 71.29%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 36%
Financial History
Updated 18/10/2026
Revenue
₹ CrLatest: 19.4-36.1% vs prev
Net Profit
₹ CrLatest: 1.8-78.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 29. Wait for confirmation.
- SMA20 falling (~9.5% over last month) — short-term momentum negative.
- RSI(14) at 29 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 42% off 52W high · 37% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
24
RS percentile
Insufficient history
1M return
-16.0%
3M return
-34.1%
6M return
-17.0%
1Y return
-
RS 1D
-17
RS 20D
-56
Sector rank
#1
Industry rank
#17
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
price below
200-DMA
unavailable
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
158 observations
19 Oct 2026Value 127.79-2.82%
RS vs Nifty 500128
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation8/30
Growth18/25
Quality14/20
Balance Sheet10/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
56
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
56/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 39.8%.
- Growth contributes 18/25 to the score.
Main drags
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
- Valuation is weaker at 8/30; verify the latest quarterly trend.
- Balance sheet is weaker at 10/15; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
32.4
PB
4.9
EV/EBITDA
20.9
ROE
24.7%
ROCE
29.3%
FCF Yield
—
Debt/Equity
0.2
MoS
+39.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
56
Previous: 56
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+39.8%
Previous: +38.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
56
56
56
56
56
56
56
56
56
56
56
56
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹40.63
-133.9% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹157.95
+39.8% MoS
PEG
0.97
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KILITCH
Small
Kilitch Drugs (India) Limited
Healthcare Services
match 138
50
27.5
10.6%
+43%
FAIR VALUE
HEALTHX
Small
Health X Platform Limited
Healthcare Services
match 137
36
—
0.4%
—
WATCHLIST
ZIMLAB
Small
Zim Laboratories Limited
Healthcare Services
match 137
17
200.0
1.6%
-6584%
OVERVALUED
LAXMIDENTL
Small
Laxmi Dental Limited
Healthcare Services
match 136
56
30.2
14.8%
+28%
FAIR VALUE
VALIANTLAB
Small
Valiant Laboratories Limited
Healthcare Services
match 136
15
43.3
-1.2%
-4939%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Gaudium IVF and Women Health Limited operates in Fertility Clinics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
67Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 39th percentile within Pharma. Main check: results consistency is weak at 38/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
10 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
52nd percentile
overall median 67 · Pharma: 39th pctile, median 70 · Small: 56th pctile, median 66
Evidence depth
Financial-only
10 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
80
strong · capital discipline
Results
38
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 71.3%.
- ▸Promoter pledge is zero.
- ▸ROCE is 29.3%.
Trust risks
- ▸Only 1 years of positive FCF.
- ▸ROCE trend is -11.7%.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
- ▸OPM spread across recent quarters is 30.9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Gaudium IVF and Women Health Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - Intimation of Post Dispatch Newspaper Advertisement for the Notice of 11th Annual General Meeting and E-Voting Information
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Sep - Gaudium IVF and Women Health Limited informed about copy of newspaper publication regarding Pre-AGM Notice of 11th Annual General Meeting to be held on Monday, …
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 16 Jul - Gaudium IVF launches AI-powered Signature Lab and begins planned 19-centre expansion on July 16, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug - Newspaper publication of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Monitoring Agency Report 13 Aug - Monitoring agency report for quarter ended June 30, 2026; no deviation, ₹25.34 crore utilized, including ₹5.76 crore Lucknow hospital GCP spending.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 Jun - Gaudium IVF and Women Health Limited has informed about Schedule of meet
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 29 May
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 May - Gaudium IVF reported FY26 revenue of ₹104.35 crore, PAT of ₹24.48 crore, and record Q4 results.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.